Biogen (BIIB) CEO says LEQEMBI IQLIK is eligible for part D reimbursement, but won't be fully reimbursed until January 2027

Biogen (BIIB) CEO says LEQEMBI IQLIK is eligible for part D reimbursement, but won't be fully reimbursed until January 2027.

Biogen's announcement regarding LEQEMBI IQLIK being eligible for Part D reimbursement is significant as it opens a revenue stream, though full reimbursement won't commence until January 2027. The delayed timeline could impact investor sentiment and stock performance in the interim, especially as market expectations adjust over this period. This development also invites scrutiny on the company's near-term earnings outlook and how it positions Biogen against peers in the biotech sector.